Biota ends laninamivir in flu after trial failure
This article was originally published in Scrip
Executive Summary
Biota Pharmaceuticals will no longer develop laninamivir octanoate (LANI) on its own following the inhaled flu treatment's failure in a 639-patient Phase II clinical trial that lost US government backing in May.